Review summary
Teaching objective: New generalized myasthenia gravis in a 34-year-old Cherokee woman recovering from major trauma, on the 2016 and 2020 international consensus guidance for MG and the KDIGO 2025 ADPKD guideline. Drooping eyelids, double vision and fatigable weakness lead to the ice pack test, acetylcholine receptor antibodies (with MuSK held in reserve), repetitive nerve stimulation (with single-fiber EMG held in reserve), chest CT for thymoma, TSH, and forced vital capacity and negative inspiratory force, with the warning signs of myasthenic crisis. Treatment covers pyridostigmine, prednisone started low and raised slowly, azathioprine as a steroid-sparing agent after TPMT and infection screening, vaccination before immunosuppression, early thymectomy under the MGTX evidence, the place of newer targeted therapies such as efgartigimod and eculizumab, and the medicines to avoid in myasthenia gravis. Her documented hereditary polycystic kidney disease adds eGFR, urine albumin, kidney ultrasound with total kidney volume and the Mayo Imaging Classification, home blood pressure, water intake and avoiding NSAIDs. Care is culturally safe, with laboratory work through Cherokee Nation Health Services near her home and her own Cherokee medicine respected. Her documented diagnosis of myasthenia gravis less than a year after the 1979 crash, and her recovery with the help of Cherokee medicine people, surgery and drug therapy, frame the episode.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| November 18, 1945 | Born in Tahlequah, Oklahoma. | CLM-0001 |
| 1956 or 1957 | Family relocates from Adair County to San Francisco. | CLM-0002 |
| 1969 | The occupation of Alcatraz shapes her activism. | CLM-0003 |
| 1976 or 1977 | Returns to Mankiller Flats in Adair County and works for the Cherokee Nation. | CLM-0004 |
| 1979 (1978 in one account) | Near-fatal head-on car crash; about 17 operations follow. | CLM-0005, CLM-0006 |
| 1981 | Returns to work with the Cherokee Nation after treatment for myasthenia gravis, diagnosed less than a year after the crash. | CLM-0007 |
| December 1985 | Becomes principal chief of the Cherokee Nation. | CLM-0008 |
| 1990 | Kidney transplant for hereditary polycystic kidney disease. | CLM-0009 |
| 1993 | Publishes her autobiography. | CLM-0012 |
| 1996 | Treated for lymphoma. | CLM-0010 |
| 1998 | Second kidney transplant; Presidential Medal of Freedom. | CLM-0010, CLM-0012 |
| 1999 | Treated for breast cancer. | CLM-0011 |
| March 2, 2010 | Announces a diagnosis of advanced pancreatic cancer. | CLM-0013 |
| April 6, 2010 | Dies at her home in rural Adair County. | CLM-0014 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Wilma Pearl Mankiller was born on November 18, 1945, in Tahlequah, Oklahoma, the capital of the Cherokee Nation, the sixth of eleven children; her father was a full-blood Cherokee. A Cherokee Nation release gave her birthplace as the W.W. Hastings Indian Hospital in Tahlequah; the Oklahoma Hall of Fame says she was born at Rock Mountain in Adair County. Anchors the true birth date and her Cherokee identity. The birthplace differs between sources; Tahlequah is used. |
confirmed | Wilson LD. Mankiller, Wilma Pearl (1945-2010). The Encyclopedia of Oklahoma History and Culture supports Brando E. Wilma Mankiller (1945-2010). Biographies supports Ex-Cherokee chief Mankiller diagnosed with cancer. Cherokee Phoenix, March 3, 2010 supports Wilma Mankiller, inducted 1994 disputes HISTMED Master Roster v3 supports |
| D | As a child she moved with her family from Mankiller Flats in Adair County to San Francisco under the Bureau of Indian Affairs relocation program (1956 or 1957 by different accounts); she later described the move as her own little Trail of Tears. History before the episode; the sources give her age at the move as 10 or 11. |
probable | Wilson LD. Mankiller, Wilma Pearl (1945-2010). The Encyclopedia of Oklahoma History and Culture supports Brando E. Wilma Mankiller (1945-2010). Biographies supports Ex-Cherokee chief Mankiller diagnosed with cancer. Cherokee Phoenix, March 3, 2010 supports |
| D | The occupation of Alcatraz Island in 1969 and her work with American Indian communities in California in the 1970s set the course of her activism. History before the episode. |
confirmed | Wilson LD. Mankiller, Wilma Pearl (1945-2010). The Encyclopedia of Oklahoma History and Culture supports Brando E. Wilma Mankiller (1945-2010). Biographies supports |
| D | She returned to eastern Oklahoma with her two daughters in the later 1970s (1976 or 1977 by different accounts), worked for the Cherokee Nation, and lived on her grandfather's allotment, Mankiller Flats, in Adair County. Anchors her home and work at the index date. Her daughters are not named and have no role in the modern episode. |
confirmed | Wilson LD. Mankiller, Wilma Pearl (1945-2010). The Encyclopedia of Oklahoma History and Culture supports Mankiller, Wilma (b. 1945). Encyclopedia of the Great Plains supports |
| D | In 1979 she was nearly killed in a head-on car crash on a curve, in which the driver of the other car, one of her best friends, died. She needed about 17 operations; accounts say her leg was barely saved from amputation and that she was told she might never walk again. The Oklahoma Hall of Fame dates the crash to 1978 and describes shattered legs, broken ribs and a crushed face. The documented anchor for the history of major trauma in the modern episode. The month of the crash is not recorded in the sources read. The friend who died is not named in this record. |
confirmed | Mankiller, Wilma (b. 1945). Encyclopedia of the Great Plains supports Ex-Cherokee chief Mankiller diagnosed with cancer. Cherokee Phoenix, March 3, 2010 supports Cherokee Ex-Chief Wilma Mankiller Dies (summary of Associated Press) supports Mankiller, Wilma. UXL Encyclopedia of World Biography (via Encyclopedia.com) supports Wilma Mankiller, inducted 1994 disputes |
| D | Her recovery was made harder by the emotional trauma of her friend's death in the crash. Recorded as the published account states it; no mental health diagnosis is made or implied. |
probable | Mankiller, Wilma (b. 1945). Encyclopedia of the Great Plains supports Fighting for her people, her health. News On 6, February 17, 2000 supports |
| D | Less than a year after the crash, while still recovering, she was diagnosed with myasthenia gravis (dated 1980 in one reference account). With help from Cherokee medicine people, surgery and drug therapy, she recovered and returned to work with the Cherokee Nation in 1981; she later became a spokesperson for the Myasthenia Gravis Foundation. The documented anchor for the modern episode. The type of surgery and the drugs are not named in the sources read; a thymectomy is therefore not recorded as history. |
confirmed | Fighting for her people, her health. News On 6, February 17, 2000 supports Mankiller, Wilma. UXL Encyclopedia of World Biography (via Encyclopedia.com) supports Mankiller, Wilma (b. 1945). Encyclopedia of the Great Plains supports Wilma Mankiller, inducted 1994 supports |
| D | She became the first woman deputy chief of the Cherokee Nation in August 1983 and principal chief in December 1985; she was elected in 1987, re-elected in 1991, and served until 1995, the first woman to lead the Cherokee Nation. History after the episode. |
confirmed | Wilson LD. Mankiller, Wilma Pearl (1945-2010). The Encyclopedia of Oklahoma History and Culture supports Brando E. Wilma Mankiller (1945-2010). Biographies supports |
| D | Hereditary polycystic kidney disease, which she called her old nemesis, led to a kidney transplant in 1990, with a kidney donated by her brother; in 1991, a year after repeated hospital stays and the transplant, she won re-election with 82 percent of the vote. The documented anchor for polycystic kidney disease in the modern episode. The donor is not named in this record. The type (autosomal dominant) is inferred from the description as hereditary and adult in onset. |
confirmed | Fighting for her people, her health. News On 6, February 17, 2000 supports Mankiller, Wilma (b. 1945). Encyclopedia of the Great Plains supports Ex-Cherokee chief Mankiller diagnosed with cancer. Cherokee Phoenix, March 3, 2010 supports |
| D | The transplanted kidney was damaged by her treatment for lymphoma in 1996, and she had a second kidney transplant in 1998. Another account says ill health, including a second kidney operation and treatment for lymphatic cancer, led her to decline a third term in 1995. Later history; the sources differ on the timing. |
probable | Fighting for her people, her health. News On 6, February 17, 2000 supports Mankiller, Wilma (b. 1945). Encyclopedia of the Great Plains supports |
| D | She was treated for breast cancer in 1999. Later history. The year comes from a February 2000 article that says she was treated 'last year'. |
probable | Fighting for her people, her health. News On 6, February 17, 2000 supports Ex-Cherokee chief Mankiller diagnosed with cancer. Cherokee Phoenix, March 3, 2010 supports |
| D | Her autobiography, Mankiller: A Chief and Her People, written with Michael Wallis, was published in 1993; she received the Presidential Medal of Freedom in 1998. In the autobiography she wrote that she wanted to be remembered for emphasizing that 'we have indigenous solutions to our problems.' History after the episode; her words anchor the culturally safe care plan. |
confirmed | Wilson LD. Mankiller, Wilma Pearl (1945-2010). The Encyclopedia of Oklahoma History and Culture supports Brando E. Wilma Mankiller (1945-2010). Biographies supports |
| D | On March 2, 2010, a news release announced that she had stage 4 metastatic pancreatic cancer; in it she wrote that she was mentally and spiritually prepared for the journey. History only; not used in the modern episode and not foreshadowed. |
confirmed | Ex-Cherokee chief Mankiller diagnosed with cancer. Cherokee Phoenix, March 3, 2010 supports Good Voice C. Former Cherokee Nation Chief Wilma Mankiller dies. Cherokee Phoenix, April 6, 2010 supports |
| D | She died on the morning of April 6, 2010, at her home in rural Adair County, Oklahoma, aged 64, of pancreatic cancer. Recorded as a fact; no detail of her last illness is used. |
confirmed | Good Voice C. Former Cherokee Nation Chief Wilma Mankiller dies. Cherokee Phoenix, April 6, 2010 supports Brando E. Wilma Mankiller (1945-2010). Biographies supports Wilson LD. Mankiller, Wilma Pearl (1945-2010). The Encyclopedia of Oklahoma History and Culture supports HISTMED Master Roster v3 supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected | resolved | confirmed | active | |
| S | Generalized myasthenia gravis, acetylcholine receptor antibody positive, MGFA class IIa, without thymoma; synthetic modern detail linked to her documented myasthenia gravis of 1980 | active | confirmed | both_with_link | CLM-0007 |
| S | Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged | active | confirmed | both_with_link | CLM-0009 |
| S | Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground | active | confirmed | both_with_link | CLM-0005 |
| S | Long-term glucocorticoid therapy for myasthenia gravis, with monitoring of glucose, blood pressure, weight, bone health, mood, sleep, eyes and infection | active | confirmed | active | CLM-0007 |
| S | Azathioprine as steroid-sparing therapy, with blood count and liver test monitoring | active | confirmed | active | CLM-0007 |
| S | Acquired absence of the thymus after robotic extended thymectomy for myasthenia gravis (pathology: thymic follicular hyperplasia, no thymoma) | active | confirmed | active | CLM-0007 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-03-09 | Hemoglobin [Mass/volume] in Blood | 12.8 g/dL Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-03-09 | Leukocytes [#/volume] in Blood by Automated count | 6.9 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-03-09 | Platelets [#/volume] in Blood by Automated count | 262 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-03-09 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-03-09 | Glucose [Mass/volume] in Serum or Plasma | 88 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-03-09 | Calcium [Mass/volume] in Serum or Plasma | 9.4 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 U/L Reference 7-45 U/L |
http://loinc.org · 1742-6 |
| S | 2026-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 U/L Reference 8-43 U/L |
http://loinc.org · 1920-8 |
| S | 2026-03-09 | Albumin [Mass/volume] in Serum or Plasma | 4.2 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-03-09 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-03-09 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.3% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-03-09 | Albumin/Creatinine [Mass Ratio] in Urine | 14 mg/g Reference Below 30 mg/g is normal (A1) |
http://loinc.org · 9318-7 |
| S | 2026-03-09 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 31 ng/mL Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-03-09 | Forced vital capacity [Volume] Respiratory system | 3.3 L Reference Lower limit of normal about 2.9 L for her age, sex and height |
http://loinc.org · 19870-5 |
| S | 2026-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | http://loinc.org · 44261-6 |
| S | 2026-03-23 | Acetylcholine receptor binding Ab [Moles/volume] in Serum | 6.8 nmol/L (high) Reference 0.02 nmol/L or less is negative |
http://loinc.org · 11034-6 |
| S | 2026-03-23 | Forced vital capacity [Volume] Respiratory system | 3.25 L Reference Lower limit of normal about 2.9 L for her age, sex and height |
http://loinc.org · 19870-5 |
| S | 2026-03-23 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-05-04 | Hemoglobin [Mass/volume] in Blood | 13.2 g/dL Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-05-04 | Leukocytes [#/volume] in Blood by Automated count | 10.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-05-04 | Platelets [#/volume] in Blood by Automated count | 284 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-05-04 | Glucose [Mass/volume] in Serum or Plasma | 104 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.76 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 105 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 U/L Reference 7-45 U/L |
http://loinc.org · 1742-6 |
| S | 2026-05-04 | Forced vital capacity [Volume] Respiratory system | 3.48 L Reference Lower limit of normal about 2.9 L for her age, sex and height |
http://loinc.org · 19870-5 |
| S | 2026-05-04 | DXA Femur [Z-score] Bone density | -0.4 Reference Above -2.0 is within the expected range for age |
http://loinc.org · 80934-3 |
| S | 2026-05-04 | DXA Lumbar spine [Z-score] Bone density | -0.7 Reference Above -2.0 is within the expected range for age |
http://loinc.org · 85394-5 |
| S | 2026-05-04 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-07-13 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-07-13 | Leukocytes [#/volume] in Blood by Automated count | 6.2 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-07-13 | Platelets [#/volume] in Blood by Automated count | 250 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.3 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-07-13 | Glucose [Mass/volume] in Serum or Plasma | 96 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.79 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-07-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 U/L Reference 7-45 U/L |
http://loinc.org · 1742-6 |
| S | 2026-07-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 8-43 U/L |
http://loinc.org · 1920-8 |
| S | 2026-07-13 | Forced vital capacity [Volume] Respiratory system | 3.4 L Reference Lower limit of normal about 2.9 L for her age, sex and height |
http://loinc.org · 19870-5 |
| S | 2026-07-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-10-12 | Hemoglobin [Mass/volume] in Blood | 12.9 g/dL Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-10-12 | Leukocytes [#/volume] in Blood by Automated count | 5.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-10-12 | Platelets [#/volume] in Blood by Automated count | 238 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-10-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-10-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 99 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-10-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 U/L Reference 7-45 U/L |
http://loinc.org · 1742-6 |
| S | 2026-10-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-10-12 | Albumin/Creatinine [Mass Ratio] in Urine | 16 mg/g Reference Below 30 mg/g is normal (A1) |
http://loinc.org · 9318-7 |
| S | 2026-10-12 | Forced vital capacity [Volume] Respiratory system | 3.62 L Reference Lower limit of normal about 2.9 L for her age, sex and height |
http://loinc.org · 19870-5 |
| S | 2026-10-12 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-08-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 2026-08-24 | Total score [AUDIT-C] | 0 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-03-09 | Body height | 163 cm | 8302-2 | S |
| 2026-03-09 | Body weight | 61.8 kg | 29463-7 | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 23.3 kg/m2 | 39156-5 | S |
| 2026-03-09 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-03-09 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2026-03-09 | Heart rate | 78 /min | 8867-4 | S |
| 2026-03-09 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-09 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-03-23 | Body height | 163 cm | 8302-2 | S |
| 2026-03-23 | Body weight | 61.6 kg | 29463-7 | S |
| 2026-03-23 | Body mass index (BMI) [Ratio] | 23.2 kg/m2 | 39156-5 | S |
| 2026-03-23 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-03-23 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-03-23 | Heart rate | 76 /min | 8867-4 | S |
| 2026-03-23 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-23 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-05-04 | Body height | 163 cm | 8302-2 | S |
| 2026-05-04 | Body weight | 63.9 kg | 29463-7 | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 24.1 kg/m2 | 39156-5 | S |
| 2026-05-04 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-05-04 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2026-05-04 | Heart rate | 80 /min | 8867-4 | S |
| 2026-05-04 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-05-04 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-07-13 | Body height | 163 cm | 8302-2 | S |
| 2026-07-13 | Body weight | 64.8 kg | 29463-7 | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 24.4 kg/m2 | 39156-5 | S |
| 2026-07-13 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-07-13 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-07-13 | Heart rate | 74 /min | 8867-4 | S |
| 2026-07-13 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-07-13 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-12 | Body height | 163 cm | 8302-2 | S |
| 2026-10-12 | Body weight | 63.6 kg | 29463-7 | S |
| 2026-10-12 | Body mass index (BMI) [Ratio] | 23.9 kg/m2 | 39156-5 | S |
| 2026-10-12 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-10-12 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-10-12 | Heart rate | 72 /min | 8867-4 | S |
| 2026-10-12 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-12 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-08-24 | Body height | 163 cm | 8302-2 | S |
| 2026-08-24 | Body weight | 64.2 kg | 29463-7 | S |
| 2026-08-24 | Body mass index (BMI) [Ratio] | 24.2 kg/m2 | 39156-5 | S |
| 2026-08-24 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2026-08-24 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-08-24 | Heart rate | 72 /min | 8867-4 | S |
| 2026-08-24 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-24 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Cherokee Nation citizen; lives at Mankiller Flats in Adair County, on land long held by her family; works for the Cherokee Nation on rural community development and has returned to part-time work since the crash
- S Household: lives with her two daughters, who are not named and are given no role in her care
- S Tobacco: never. Alcohol: none. No drug use
- S Health care: eligible for Cherokee Nation Health Services as a citizen; prefers laboratory work at a Cherokee Nation clinic near her home; drives herself again since the winter, about an hour to this clinic
- S Traditional medicine: she has her own Cherokee medicine and will decide whether and how it is part of her care; she shares any plant medicines with the clinic so that interactions can be checked; nothing further is asked or recorded
- S Strengths: determination through a long recovery, deep ties to her community, and a practical way of solving problems
Functional status
- S Independent in daily activities; walks without help indoors and with a cane on rough ground after the leg operations; by evening she tires holding her arms up to brush her hair and must rest her jaw while eating
Mental status
- S Alert, direct and composed; tired; speaks of the hard year since the crash and the loss of her friend; PHQ-9 score 7
Allergies and medications
Allergies
- S No known allergy
Medications
- S Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating
- S Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before meals
- S Pyridostigmine bromide 60 mg oral tablet, one tablet three times daily, 30 to 45 minutes before meals
- S Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mg
- S Prednisone 5 mg oral tablet, tapering from 40 mg each morning by 5 mg every two to three weeks
- S Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) daily
- S Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with food
- S Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet daily
- S Sulfamethoxazole 800 mg / trimethoprim 160 mg oral tablet, one tablet three times a week, while prednisone is 20 mg or more with azathioprine
- S Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain
Procedures and immunizations
Procedures
- S CT of the chest with contrast: residual thymic tissue appropriate for age, without a mass; no thymoma; healed rib fractures on the right; lungs clear
- S Ultrasound of the kidneys: both kidneys enlarged with many cysts (right 14.1 cm, left 14.6 cm); total kidney volume by the ellipsoid method 594 mL, height-adjusted 364 mL/m, Mayo Imaging Class 1B; several small liver cysts; no stones
- S Repetitive nerve stimulation at 3 Hz with needle-free surface recording: reproducible decrement of 22 percent in the nasalis and 18 percent in the trapezius, with partial repair after exercise; normal sensory and motor conduction
- S Bedside measurement of breathing: negative inspiratory force -70 cm H2O, single-breath count to 32, with the seated FVC
- S Advance care planning conversation, about 20 minutes, with her consent
- S Robotic thoracoscopic extended thymectomy from the right, with two nights in hospital and no postoperative myasthenic worsening; pathology: thymic follicular hyperplasia, no thymoma
Immunizations
- S 2025-06-12: Tdap vaccine, at the hospital after the crash
- S 2026-03-23: Pneumococcal conjugate vaccine PCV20, before immunosuppression
- S 2026-03-23: Recombinant zoster vaccine, dose 1 of 2, before immunosuppression
- S 2026-08-24: Recombinant zoster vaccine, dose 2 of 2
- S 2026-10-12: Inactivated influenza vaccine, this season
- S 2026-10-12: COVID-19 vaccine, mRNA, this season
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1979 (1978 in one account): Near-fatal head-on car crash with about 17 operations, with fractures of the legs, ribs and face (CLM-0005)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| A confirmed diagnosis and treatment plan within three weeks | 2026-03-23 | completed | AChR antibodies, nerve stimulation, chest CT and kidney ultrasound done; generalized MG diagnosed and treatment begun at two weeks |
| Minimal manifestation status (MG-ADL 0 to 1) within a year, with prednisone at 7.5 mg or less | 2026-10-12 | active | MG-ADL 7 at diagnosis, 1 at seven months; prednisone 15 mg and still tapering |
| No myasthenic crisis, and she knows the warning signs and the medicines to avoid | 2026-10-12 | completed | No crisis; FVC 3.25 to 3.62 L; she carries a wallet card and the list of medicines to avoid |
| Kidney health: eGFR and urine albumin yearly, home blood pressure 110/75 mm Hg or lower if it rises above 130/85, 2 to 3 liters of water a day, and no NSAIDs | 2026-10-12 | completed | eGFR normal; urine albumin normal; home blood pressure about 116/74 without medicine |
| Return to full-time work for the Cherokee Nation | 2026-10-12 | completed | Back at work full time from the seventh month |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Neuromuscular neurology consultation within two weeks for suspected generalized myasthenia gravis: diagnosis, immunotherapy, thymectomy and safety | completed | GL-MG-2020, GL-MG-2016 |
| Diagnostic tests: acetylcholine receptor binding antibodies (MuSK antibodies if negative), repetitive nerve stimulation (single-fiber EMG if unclear), CT of the chest with contrast for thymoma, TSH, and seated FVC with negative inspiratory force | completed | GL-MG-2016, GL-MG-2020 |
| Safety: pyridostigmine 30 mg three times daily as a trial; warning signs of myasthenic crisis (breathlessness lying flat, weak cough, trouble swallowing, slurred speech) with emergency care the same day; a wallet card and the list of medicines to avoid, including fluoroquinolones, aminoglycosides, macrolides, magnesium by vein, beta-blockers and telithromycin | completed | GL-MG-2016, GL-MGFA-DRUGS |
| Kidney care for her hereditary polycystic kidney disease: kidney ultrasound with total kidney volume, eGFR and urine albumin, home blood pressure readings, 2 to 3 liters of water a day spread through the day, less salt, and acetaminophen instead of NSAIDs | completed | GL-KDIGO-ADPKD-2025 |
| Culturally safe care: laboratory work at a Cherokee Nation Health Services clinic near her home, results shared with this clinic; time given to explain each test and medicine plainly; her own Cherokee medicine respected, with any plant medicine shared so that interactions can be checked, and nothing further asked | completed | GL-CNHS, GL-MG-2016 |
| Immunotherapy: pyridostigmine 60 mg four times daily; prednisone 10 mg each morning rising by 10 mg a week to 40 mg; azathioprine after TPMT activity and hepatitis B and tuberculosis screening, from 50 mg to 150 mg daily; pneumococcal and recombinant zoster vaccines before immunosuppression; no live vaccines | completed | GL-MG-2016, GL-MG-2020, GL-CDC-IMZ-2026 |
| Thymectomy: thoracic surgery assessment for robotic extended thymectomy once she is stable, for AChR antibody-positive generalized MG at 34 | completed | GL-MG-2020, GL-MGTX-2016 |
| Glucocorticoid safety: calcium and vitamin D, DXA within the first months, glucose and hemoglobin A1c, blood pressure and weight at each visit, sleep and mood, eye examination yearly, and Pneumocystis prophylaxis while prednisone is 20 mg or more with azathioprine | completed | GL-ACR-GIOP-2022, GL-MG-2016 |
| Azathioprine monitoring: blood count and liver tests every one to two weeks for the first two months, then every three months | completed | GL-MG-2016 |
| Newer targeted therapies (efgartigimod, eculizumab or ravulizumab) kept in reserve for refractory disease or intolerance of standard immunotherapy; complement inhibitors would need meningococcal vaccination first | completed | GL-MG-2020, GL-ADAPT-2021 |
| Standing laboratory orders at the Cherokee Nation Health Services clinic near her home for every azathioprine blood test, with results sent to this clinic and a nurse call for each result | completed | GL-CNHS, GL-MG-2016 |
Planned encounters
- 2026-03-09 — New patient with six weeks of drooping eyelids, double vision and fatigable weakness while recovering from a car crash: examination, ice pack test, breathing measurements, baseline tests, a pyridostigmine trial, kidney screening, and neuromuscular neurology referral (ENC-001)
- 2026-03-23 — Two-week review with the neuromuscular neurology consultation the same day: antibody, nerve stimulation, chest CT and kidney ultrasound results, the diagnosis, and the treatment plan (ENC-002)
- 2026-05-04 — Six-week review on pyridostigmine and prednisone: strength, breathing, glucose and blood pressure, bone density, start of azathioprine, and the thymectomy plan (ENC-003)
- 2026-07-13 — Review five weeks after thymectomy: recovery, pathology, azathioprine monitoring, the prednisone taper, and kidney care (ENC-004)
- 2026-08-24 — Periodic adult preventive visit (ENC-006)
- 2026-10-12 — Seven-month review: minimal manifestation status, prednisone and pyridostigmine reduction, azathioprine safety, kidney screening, and plans for the year (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Preventive Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Neuromuscular Neurology referral
- Neuromuscular Neurology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Preventive Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Neuromuscular Neurology referral (XML)
- Neuromuscular Neurology consultation (XML)
Sources
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the slow prednisone rise, azathioprine after TPMT and infection screening, Pneumocystis prophylaxis, early robotic thymectomy at 34 with AChR antibodies and no thymoma, newer targeted therapies held in reserve, the missed early azathioprine blood tests, the ADPKD staging (Mayo 1B, so no tolvaptan) and the decision not to start a blood pressure medicine at normal-high readings. |
| provenance review | not_started | Recent-death rule: only what she made public and what obituaries and reference works reported: the Oklahoma Historical Society, the National Women's History Museum, the Encyclopedia of the Great Plains, the Oklahoma Hall of Fame, Encyclopedia.com, News On 6 (2000) and the Cherokee Phoenix (2010). Her autobiography and the New York Times obituary were not read directly. |
| safe messaging review | not_started | Her husband, daughters, brother and the friend killed in the crash are not named and are given no statement, decision or health fact. The emotional trauma of the crash is recorded as published, marked sensitive, with no diagnosis. Her Cherokee identity and medicine are described without stereotype and without describing any practice. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.